Global study decodes HIV drug resistance after dolutegravir failure
NCT ID NCT06285110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 1,100 people with HIV whose dolutegravir-based treatment stopped working. Researchers collected blood samples to find drug-resistance mutations in the virus. The goal is to understand why some treatments fail and how to better manage HIV in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors choose better HIV medications for people whose current treatment fails.
What could go wrong
This is an observational study, not a treatment trial. It only looks at what went wrong, not how to fix it. Results may not apply to all HIV subtypes or regions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACONDA Centre de Prise en Charge et de Formation (CePReF)
Abidjan, Côte d’Ivoire
-
Centre de Traitement Ambulatoire
Brazzaville, Republic of the Congo
-
Centre de Traitement Ambulatoire
Pointe-Noire, Republic of the Congo
-
Centre for Infectious Disease Research Zambia (CIDRZ)
Lusaka, Zambia
-
Centre médical de suivi des donneurs de sang, CNTS
Abidjan, Côte d’Ivoire
-
Centro Medico Huesped
Buenos Aires, Argentina
-
HIV-NAT/Thai Red Cross AIDS Research Center (TRCARC)
Bangkok, Thailand
-
Hopital de Jour du Centre Hospitalier Universitaire (CHU Souro Sanou)
Bobo-Dioulasso, Burkina Faso
-
Hospital Jamot
Yaoundé, Cameroon
-
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico
-
Instituto Nacional de Infectiologia Evandro Chagas - Fiocruz
Rio de Janeiro, Brazil
-
Lighthouse clinic
Lilongwe, Malawi
-
Martin Preuss Centre
Lilongwe, Malawi
-
Masaka Regional Referral Hospital / AHF Uganda Cares
Masaka, Uganda
-
Mbarara University of Science and Technology / Mbarara ISS Clinic (MUST)
Mbarara, Uganda
-
Moi University, AMPATH
Eldoret, Kenya
-
National Centre for HIV/AIDS, Dermatology and STDs (NCHADS)
Phnom Penh, Cambodia
-
National Institute for Medical Research (NIMR)
Kisesa, Tanzania
-
Newlands Clinic
Harare, Zimbabwe
-
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
-
Regional Hospital Limbe
Limbe, Cameroon
-
Research for Development, Einstein-Rwanda Research and Capacity Building Program
Kigali, Rwanda